Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $46.43

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus recommendation of “Buy” by the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $46.43.

DNTH has been the topic of several research analyst reports. Wedbush decreased their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James boosted their price objective on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC increased its stake in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $112,000. The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $236,000. Fred Alger Management LLC grew its position in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after acquiring an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $265,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 3.5 %

Shares of NASDAQ:DNTH opened at $24.68 on Monday. The company has a market capitalization of $730.45 million, a PE ratio of -9.87 and a beta of 1.74. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The firm has a 50 day simple moving average of $26.60 and a 200-day simple moving average of $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.